Amyloid-related imaging abnormality edema is a known side effect of anti-amyloid monoclonal antibody treatments, such as Leqembi and donanemab Kisunla.
Asian patients are rarely represented in large TAVR trials, the authors wrote, so they focused on nearly 1,200 patients from South Korea to provide a fresh perspective.